Scars - Pipeline Insight, 2024

This “Scars - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Scars: Understanding

Scars: Overview

Scars are a complex outcome of the body's natural healing process following injury or trauma, characterized by abnormal tissue that lacks the structure and function of normal skin. They can significantly impact both physical and mental health, often leading to aesthetic concerns and functional impairments. Research indicates that scars can cause physical discomfort and psychological distress, including anxiety and depression, particularly in cases of severe scarring from burns or surgeries.

Various treatment options exist, including surgical excision, hormonal therapy, and newer approaches like stem cell therapies, but none are universally effective. The need for improved scar management strategies is critical, as scars not only affect appearance but also hinder physiological functions and can lead to social and emotional challenges for patients.

Scars manifest as fibrous tissue that forms at the site of skin injury, with signs and symptoms varying based on the type and severity of the scar. Initially, scars may appear firm, red, or purple, gradually lightening and flattening over time. Abnormal scarring, such as hypertrophic or keloid scars, can present with chronic pain, itching, and tenderness, persisting long after the initial injury has healed. The texture of scars often differs from normal skin, appearing smooth and shiny due to the lack of hair follicles, sweat glands, and pigmentation. In some cases, scars may lead to functional limitations, particularly if they form across joints or areas of movement, causing discomfort or restricted mobility.

Pathologically, scars can be classified into various types, such as hypertrophic scars and keloids, which arise due to abnormal fibroblast activity and excessive collagen deposition. Histologically, scars exhibit a thickened epidermis, a flattened dermo-epidermal junction, and an atypical arrangement of collagen fibers, predominantly type III collagen, deviating from the normal basket-weave pattern of healthy skin. The pathogenesis of raised scars involves complex mechanisms, including the role of transforming growth factor-beta (TGF-β), which stimulates fibroblast proliferation and collagen synthesis while inhibiting collagen degradation.

Scars are primarily diagnosed through visual inspection by healthcare professionals, who assess their characteristics such as size, location, and texture. Dermatologists often evaluate the scar's history, including the cause of the injury and the healing process, to determine the type of scar, which can include hypertrophic, keloid, atrophic, or contracture scars. In some cases, a biopsy may be necessary to confirm the diagnosis, especially if there are atypical features or if the scar is suspected to harbor other dermatological conditions.

Scars can be treated through a variety of methods, depending on their type and severity. Topical treatments like silicone gels, creams, and ointments can help soften and flatten scars, while steroid injections or laser therapy are effective for raised scars. For severe or disfiguring scars, surgical options like excision, skin grafts, or flap closure may be recommended to improve appearance and function.

"Scars- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scars pipeline landscape is provided which includes the disease overview and Scars treatment guidelines. The assessment part of the report embraces, in depth Scars commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scars collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Scars R&D. The therapies under development are focused on novel approaches to treat/improve Scars.

Scars Emerging Drugs Chapters

This segment of the Scars report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Scars Emerging Drugs

INV001: Innovo Therapeutics

INV-001 is a topically administered small-molecule drug in development for the prevention and treatment of hypertrophic scars and keloids. It works by inhibiting HSP47, a protein critical for collagen formation, transport, and extracellular secretion, which plays a significant role in scar formation. By targeting HSP47, INV-001 reduces collagen production in fibroblasts, effectively mitigating trauma- and surgery-induced scars while not impairing normal wound healing. Preclinical studies have demonstrated its efficacy in both burn-induced scars in mini pig models and incision-induced scars in SD rats. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Scars.

TRTP-101: CellinCells

TRTP 101 is an investigational stem cell therapy developed by Originator Cell, currently in Phase I trials. As part of the broader class of tissue replacement therapies, TRTP 101 is designed to leverage the regenerative potential of stem cells to repair or replace damaged tissues. Its mechanism of action involves the delivery of stem cells to the affected area, where they differentiate into specific tissue types needed for regeneration. This process aims to restore function and structure in damaged or scarred tissues, making it particularly relevant for conditions that result in tissue loss or scarring. The therapy holds promise for improving recovery and reducing long-term damage by promoting natural tissue regeneration.

Scars: Therapeutic Assessment

This segment of the report provides insights about the different Scars drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Scars

• There are approx. 8+ key companies which are developing the therapies for Scars. The companies which have their Scars drug candidates in the most advanced stage, i.e. Phase II include, Innovo Therapeutics.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Scars pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scars: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Scars therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scars drugs.

Scars Report Insights

• Scars Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Scars Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Scars drugs?
• How many Scars drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scars?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Scars therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Scars and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kringle Pharma
• Innovo Therapeutics
• CellinCells
• CellionBioMed
• Syntara

Key Products

• KP100
• INV001
• TRTP-101
• CBM 401
• SNT-5505

This product will be delivered within 2 business days.